Retina2021年1月のTHE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES: A Review、LANCET2022年2月のEfficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials、LANCET2022年2月のEfficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trialsを読みました
